During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events.
Jean-Bernard Durand, MD
Advertisement
Articles by Jean-Bernard Durand, MD
Advertisement
Latest Updated Articles
Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted TherapiesPublished: March 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
2
Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML
3
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma
4
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL
5
